Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
Are you using any specific testing platform for risk stratification in identifying early stage non-small cell lung cancer patients at risk for recurrence and likely to benefit from adjuvant chemotherapy?
Related Questions
Which regimen do you recommend for chemoradiation for a patient with locally advanced, inoperable thymic tumor in the setting of CKD Stage III?
What chemotherapy regimens would be appropriate for cisplatin-ineligible patients to receive concurrently with definitive radiotherapy for locally advanced (inoperable) thymic carcinoma?
What would be your approach in a patient who presented with a solitary brain metastasis that resolved after chemo without local therapy?
What is your preferred approach for managing oligoprogressive NSCLC during second-line or later systemic therapy if patient is otherwise responding well at other sites of disease?
For those early stage resectable NSCLC patients who received neoadjuvant chemoimmunotherapy as per Checkmate816 and did not attain a pCR, what are the adjuvant immunotherapy treatment strategies if EGFR negative?
What second line therapy do you use for metastatic thymoma that recurs following CAP?
Which targeted therapies should we be more cautious of giving after recent immunotherapy in NSCLC?
In patients with driver mutation positive NSCLC who have progressed on targeted therapy and are planned for chemotherapy as the next line of treatment, for which driver alterations do you add in IO and which do you omit IO?
Is there a role for surgical debulking, local RT or subsequent line of chemotherapy for a patient with stable malignant thymoma but active myasthenia gravis?
Would you offer adjuvant osimertinib in a patient with complete pathologic response to neoadjuvant platinum doublet for a stage IIIA resected EGFR mutant lung adenocarcinoma?